Advantages of the use of insulin aspart in insulin pump therapy in type 1 diabetic patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Keeping blood glucose close to normoglycemia is associated with the achievement of optimal short-term and long-term targets of treatment of patients with diabetes mellitus type 1 (T1DM), that requires an intensified insulin therapy using multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Many patients with T1DM are unable to achieve glycemic control using MDI. In contrast to MDI, CSII allows more flexibility in daily life, helps to increase the effectiveness of treatment, improves the quality of life and adherence to treatment. These data from the real clinical practice have proven the clinical trials data, that insulin aspart in CSII has the advantages in terms of decreased variability of glycemia, improved glycemic control, reduction of the hypoglycemia rate and daily insulin requirements in compare with MDI in T1DM patients, and prevents the dawn phenomenon.

Full Text

Restricted Access

About the authors

E. V Kovrigina

SBHCI “Chelyabinsk Regional Clinical Hospital"; FSBEI HE “South Ural State Medical University" of RMH

Email: katarina_1981@mail.ru

V. L Tyulganova

SBHCI “Chelyabinsk Regional Clinical Hospital"; FSBEI HE “South Ural State Medical University" of RMH

Endocrinologist; Teaching Assistant at the Department of Hospital Therapy

References

  1. Nathan D.M., Cleary P.A., Backlund J.Y, et al. Diabetes control and complications trial/ epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group intensive diabetes treat-ment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005;353: 2643-53.
  2. Nathan D.M., Zinman B., Cleary P.A., Backlund J.Y, Genuth S., Miller R., Orchard T.J. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch. intern. Med. 2009;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.
  3. Albers J.W., Herman W.H., Pop-Busui R., Feldman E.L., Martin C.L., Cleary P.A., Waberski B.H., Lachin J.M., Group ftDER. Effect of Prior intensive insulin Treatment During the Di-abetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes interventions and Complications (EDiC) Study. Diabetes Care. 2010;33(5): 1090-96.
  4. White N.H., Sun W., Cleary P.A., Tamborlane W.V., Danis R.P., Hainsworth D.P., Davis M.D., Group ft D.-E.R. Effect of Prior intensive Therapy in Type 1 Diabetes on 10-Year Progres-sion of Retinopathy in the DCCT/ EDiC: Comparison of Adults and Adolescents. Diabetes. 2010;59(5):1244-53.
  5. DCCT/EDiC Research Group, de Boer I.H., Sun W., et al. intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 2011;365(25):2366-76.
  6. Bryant W., Greenfield J.R., Chisholm D.J., Campbell L.V. Diabetes guidelines: easier to preach than to practise? Med. J. Aust. 2006;185(6):305-9.
  7. Govan L., Wu O., Briggs A., et al. Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Net-work Epidemiology Group. Diabetes Care. 2011;34(9): 1992-97.
  8. Шестакова М.В., Майоров А.Ю., Филиппов Ю.И. и др. Федеральные клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом. М., 2014.
  9. Дедов И.И., Петеркова В.А., Кураева Т.Л., Емельянов А.О., Андрианова Е.А., Лаптев Д.Н. Помповая инсулинотерапия сахарного диабета у детей и подростков. Российский консенсус детских эндокринологов. Проблемы эндокринологии. 2012;58(2):3-18.
  10. Renard E. Insulin pump use in Europe. Diabetes Technol Ther. 2010; 2(Suppl. 1):S29-S32.
  11. Kerr D., et al. Stability and Performance of Rapid-Acting Insulin Analogs Used for Continuous Subcuta-neous Insulin Infusion: A Systematic Review. J. Diabetes Sci. Technol. 2013;7(6):1595-606.
  12. Poulsen C., Langkjaer L., Worsoe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol. Ther. 2007;9(1): 26-35.
  13. Bode B.W. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibil-ity of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr. Pract. 2011;17:271-80.
  14. van Bon A.C., Bode B.W., Sert-Langeron C., DeVries J.H., Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol. Ther. 2011;13:607-14.
  15. Poulsen C., Langkjaer L., Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol. Ther. 2005;7(1):142-50.
  16. Bartolo P.D., Pellicano F., Scaramuzza A., Sardu C., Casetti T., Bosi E., Miselli V., Brandolini S., Fabbri T., Meandri P., Cannatà F. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol. Ther. 2008;10(6): 495-98.
  17. Weinzimer S.A., Ternand C., Howard C., et al.; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31(2):210-15.
  18. Tamborlane W.V., Renard E., Wadwa R.P, et al. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J. Diabetes. 2015;7(2): 270-78.
  19. IMS Health database. 2014. MiDAS Database Quantum, December 2014.
  20. Hirsch I.B., Bode B.W., Garg S., et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSii. Diabetes Care. 2005;28: 533-38.
  21. Jeitler K., Horvath K., Berghold A., et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51:941-51.
  22. Pickup J.C., Sutton A.J. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-74.
  23. Misso M.L., Egberts K.J., Page M., O'Connor D., Shaw J. Continuous subcutaneous insulin infusion (CSii) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst. Rev. 2010;1 CD005103.
  24. Radenkovié S.P., Pesié M.M., Velojić Golubović M.D., et al. Continuous subcutaneous insulin infusion vs. multiple daily injections. Cen. E. J. Med. 2011;6:575.
  25. Pozzilli P., Battelino T., Danne Th., Hovorka R., et al. Continuous subcutaneous insulin infusion in dia-betes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab. Res. Rev. 2015. doi: 10.1002/dmrr.2653.
  26. Steineck I., Cederholm J., Eliasson B., et al. insulin pump therapy, multiple daily injections, and cardio-vascular mortality in 18168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234.
  27. Madonna R., De Caterina R. Atherogenesis and diabetes, focus on insulin resistance and hyperinsuline-mia. Rev. Esp. Cardiol. 2012;65(4):309-13.
  28. Schnell O., Cappuccio F., Genovese S., et al. Type 1 diabetes and cardiovascular disease. Schnell et al. Cardiovascular Diabetology. 2013;12:156-65.
  29. de Ferranti S.D., de Boer I.H., Fonseca V., et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843-63.
  30. Onitilo A.A., Engel J.M., Glurich I., Stankowski R.V., Williams G.M., Doi S.A. Diabetes and cancer: risk, survival, and implications for screening. Cancer Causes Control. 2012;23:967-81.
  31. Harding J.L., Shaw J.E., Peeters A., Cartensen B., Magliano D.J. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse. Causation. Diabetes Care. 2015; 38:264-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies